EXHIBIT 29

Records demands, and Blank Rome LLP letter of June 24, 2026

Nejmeh v. Theriva Biologics, Inc., No. 3:26-cv-00705-ART-CSD (D. Nev.)
Cited in the First Amended Verified Complaint, paragraph(s) 76

Personal identifiers redacted under LR IC 6-1.

FORM OF SWORN DEMAND FOR INSPECTION OF CORPORATE RECORDS

DELIVERED VIA CERTIFIED MAIL – RETURN RECEIPT REQUESTED

DATE: June 15, 2026

TO:
Theriva Biologics, Inc.
Attn: Corporate Secretary
9605 Medical Center Drive, Suite 270
Rockville, Maryland 20850

CC:
Theriva Biologics S.L. (Spain Office)
Attn: Managing Directors / Corporate Secretary
Carrer Torrent de Can Ninou, naus 5-6
08150 Parets del Vallès (Barcelona) Spain

Leslie Marlow, Esq.
Blank Rome LLP
1271 Avenue of the Americas
New York, NY 10020

FROM:
Mark Nejmeh
P.O. Box 589
Clifton, NJ 07012
realroofers@gmail.com

RE: FORMAL SWORN DEMAND FOR INSPECTION OF CORPORATE RECORDS AND FINANCIAL DOCUMENTS

Dear Corporate Secretary,

Pursuant to Nevada Revised Statutes (**NRS**) **78.105**, **78.257**, and applicable common law, I, Mark Nejmeh, hereby make a formal, sworn demand to inspect and copy the following corporate and financial records of Theriva Biologics, Inc. (the "Company").

1. Stockholder Status and Standing
I have been a stockholder of record for over four (4) years, maintaining continuous ownership since at least June 2022. This holding history grants me statutory rights under Nevada law to inspect the Company's records.

2. Specific Records Demanded for Production
I demand the Company produce the following materials within **five (5) business days**.

These should be delivered digitally to **realroofers@gmail.com** or in writing to my mailing address above:

- **Official Meeting Minutes & Audio:** The complete records for special meetings held on **December 15, 2025**; **February 11, 2026**; **April 9, 2026**; and **June 5, 2026** (the latter held at the Barcelona facility). This must include the specific record of the **December 22, 2025** continuation date formally announced on December 15. [1]
- **Voting Records and Proxy Tabulation:** All raw proxy receipt logs and certified voting reports (e.g., from Broadridge/Computershare) for every special meeting since December 15, 2025, including the June 5, 2026 session where no quorum was claimed.
- **Attorney Communication Logs:** All records, logs, or memos regarding the two (2) telephone calls initiated by Leslie Marlow, Esq., to my personal phone within one hour of the December 15, 2025 meeting.
- **Proxy Solicitor Invoices:** Copies of all paid invoices and billing statements from the Company's proxy solicitation firms for services rendered from December 2025 to the present.

3. Legitimate Business Purpose

This inspection is essential to:

1. **Investigate Procedural Missteps:** To verify if the Company failed to hold the formally announced December 22 session, which may invalidate subsequent meetings and the 16.2 million warrant inducement agreement. [1]
2. **Investigate Potential Mismanagement:** To review the telephonic pressure applied by counsel attempting to "start over" immediately following a failed meeting and the costs associated with repeated adjournments and international meetings.
3. **Verify Voting Integrity:** To independently audit quorum determinations and voting patterns for the warrant proposal.

4. Form of Delivery

Per Nevada law, I request these records in electronic form. If any requested records are maintained only in digital form, they must be converted to a clear, legible paper form if not delivered via email.

Sincerely,

Mark Nejmeh

VERIFICATION UNDER OATH (Affidavit)

STATE OF NEW JERSEY) Arkansas
) ss.
COUNTY OF Washington)

I, Mark Nejmeh, being first duly sworn, depose and state under penalty of perjury that:

1. I am a stockholder of Theriva Biologics, Inc.;
2. I have read the foregoing Demand and the facts, ownership assertions, and stated purposes therein are true and correct to the best of my knowledge;
3. This inspection is not desired for a purpose other than the business of the corporation;
4. I have not at any time sold or offered for sale any list of stockholders or aided any person in procuring such records.

Mark Nejmeh (Sign only in front of Notary)

Subscribed and sworn to before me on this 15 day of June, 2026.

Notary Public Signature

KIM JONES
Notary Public - Arkansas
Washington County
Commission # 12700833
My Commission Expires Apr 20, 2027


CERTIFIED MAIL® RECEIPT
OFFICIAL USE
UNITED STATES POSTAL SERVICE
OFFICIAL USE
3806, Registered Mail Receipt
931 6335 7397 84

WITNESS STATEMENT — SPECIAL MEETING OF STOCKHOLDERS
Theriva Biologics, Inc. · 15 December 2025

PART 1 — WHO YOU ARE

1. Your full legal name: Paul Bernhardt

2. Your address: [redacted] Toms River NJ [redacted]

3. Are you a stockholder of Theriva Biologics, Inc. (NYSE American: TOVX)? If yes, roughly how many shares did you hold on 15 December 2025, and were they held in your own name with the transfer agent or through a broker?

Answer: I have 157,000 shares held with Charles Schwab NY

4. How do you know Mark Nejmeh, and for how long?

Answer: I know mark for approximately 1 year. We met at the local gym in Brick NJ.

PART 2 — GETTING THERE

5. How did you learn the meeting was taking place, and roughly when?

Answer: I learned of the meeting thru the proxy vote announcement from my broker approximately November 2025

6. Did you receive proxy materials from the company? If so, did you vote in advance or not, and why?

Answer: I voted in advance of the December 15, 2025

7.Where was the meeting held, and what time did you arrive?

Answer: The meeting was held at Theriva Biologics corporate headquarters, 9605 Medical Drive, Suite 270, Rockville MD, 20850

PART 3 — WHAT HAPPENED IN THE ROOM

8.Who was present? Give names where you know them, and describe anyone you do not know (company staff, lawyers, other shareholders).

Answer: Besides myself attendees are listed here: Mark Nejmeh Shareholder, Gary Pitoniak, Shareholder, A heavyset person who ran the zoom computer referred by Stephen Shallcross as "TJ" who is the company controller, Stephen Shallcross, CEO on zoom although I could only hear his voice, the video was not projected to the room, Lesley Marlow ESQ corporate attorney who was also voice only not shown on video.

9.Describe what happened, in the order it happened, from when you entered the room to when you left.

Answer: First Stephen Shallcross said there was no quorum (with 3 shareholders present) and said we could adjourn to 12/22/26 at which point Mark Nejmeh said I have questions. Mr Nejmeh asked how many outstanding shares there were currently. Mr Shallcross said I don't know and Lesley Marlow said to Mr Shallcross that he must answer. I believe Mr Shallcross said 33 million shares were outstanding. Nejmeh asked if Mr Shallcross was continuing a pattern of a stock dilution death spiral in tovx similar to the fate of prior companies where Shallcross had direct involvement and Mr Nejmeh also asked whether Mr Shallcross et al were working in an organized criminal pattern which Mr Shallcross denied. A this point Ms Marlow laughed. Then Mr Nejmeh asked how much new capital the warrant proposal would bring in, Mr Shallcross declined to comment. Then Mr Shallcross and Lesley Marlow proposed a new meeting for the following week on 12/22/25. All shareholders said they would attend. I said I'll be there as well. I then asked TJ for a transcript of the meeting and he referred me to the Theriva public relations office. I called the office and left a message requesting a meeting transcript and followed up with email but the company never responded.

10.Was anything said about a quorum? Write down what was said and who said it, as close to word for word as you can manage.

Answer: Stephen shall cross said we don't have a quorum.

11.Was anything said about holding the meeting again on another date?

Answer: Stephen Shallcross announced to the group there would be a new meeting held in one week on 12/22/26. No one was asked to vote on having a meeting on 12/22/26.

12. Did any shareholder present say anything in response? What, and who?

Answer: I said I'll attend, Mr Nejmeh said he would attend, Gary Pitoniak said he would attend.

13.Have you discussed this meeting with anyone else who was there, before writing this statement? If yes, with whom, and roughly when?

Answer: I discussed the meeting with Mark Nejmeh and Gary Pitoniak after the meeting on 12/22/26 in the Starbucks inside the hotel since it was a very cold December day. I have posted my comments about the meeting to stock twits and also after the meeting made a note to myself via email. See attached

PART 4 — ANYTHING AFTERWARD

14.Did anyone from the company, or any lawyer, contact you after the meeting? If so: who, when, by what method, and what was said?

Answer: No one contacted me after the meeting.

15. Have you written to the company about the meeting, or requested any records? If so, attach a copy of what you sent and any reply.

Answer: At the meeting I requested from TJ a copy of the meeting transcript as stated earlier. He referred me to the Theriva public relations department, yet I received no response from them. See attached email sent 12/16/25 to Chris Calabrese @ lifesciadvisors.com. requesting transcript.

PART 5 — ANYTHING ELSE

16. Is there anything else you saw or heard that day that you think matters? Write it here.

DECLARATION

I have read the above. **Every word of this statement was written by me.** No one told me what to write. It is a true account of what I personally saw and heard, to the best of my memory. Where I did not remember something, I said so.

Signature: Paul Bernhardt

Printed name: Paul Bernhardt

Date: 8/27/26

Notary

State of New Jersey · County of Ocean

Subscribed and sworn to before me this 26th day of August, 2026

Notary Public: Lynn R O'Toole

My commission expires: 9/28/24

LYNN R. O'TOOLE
Notary Public, State of New Jersey
My Commission Expires 9/28/2026

Transcript request for special meeting 12/15/25

From: paul bernhardt (pfbernhardt@yahoo.com)
To: ccalabrese@lifescladvisors.com
Bcc: pfbernhardt@yahoo.com
Date: Tuesday, December 16, 2025 at 12:44 PM EST

Hello Chris,
I attended the special meeting yesterday and asked the person running the laptop zoom if I could get a transcript meeting. Sorry I don't know his name but he directed me to you with my request. Please advise.

Thank you
Paul Bernhardt

Así eres tú

Así eres tú

Así eres tú

Paul Bernhardt
[redacted]
Toms River, New Jersey [redacted]
917 676 8985
pfbernhardt@yahoo.com
June 4, 2026
Via Certified Mail #
Via Federal Express # 872671856082

Theriva Biologics SL
Attn: Corporate Secretary & Board of Directors
Carrer Torrent de Can Ninou, naus 5-6
08150 - Parets del Vallès (Barcelona)
Spain

Theriva Biologics, Inc.
Attn: Corporate Secretary & Board of Directors
9605 Medical Center Drive, Suite 270
Rockville, MD 20850

CC:Leslie Marlow, Esq.
Blank Rome LLP
1271 Avenue of the Americas New York, NY 10020

ORIGIN ID:HJKO
PAUL BERNHARDT
[redacted]
TOMS RIVER, NJ
UNITED STATES US

TO CC: LESLIE MARLOW, ESQ.
BLANK ROME LLP
1271 AVE OF THE AMERICAS
NEW YORK CITY NY 10020
(000) 000-0000 REF:

FedEx Express

MON - 08 JUN 5:00P
** 2DAY **
DSR
10020
NY-US EWR

TRK# 0201 8726 7185 6082

K2 QNYA

RE: DEMAND FOR CORPORATE RECORDS UNDER NRS § 78.257 – DECEMBER 15, 2025 SPECIAL MEETING MINUTES AND RAW VOTING LEDGERS To the Board of Directors, Corporate Secretary, and Corporate Counsel: I am writing to issue a strict, formal demand for corporate records. I am an individual investor who has continuously held shares of Theriva Biologics, Inc. ("TOVX" or the "Company") for nine months. My nine month holding history grants me an absolute statutory right under Nevada Revised Statutes (NRS § 78.257) to inspect and copy the books, records, and voting ledgers of the Company.This demand specifically concerns the corporate minutes, proxy voting ledgers, and administrative actions surrounding the Special Meeting of Stockholders called on December 15, 2025, at the Company's office in Rockville, Maryland.

588 Route 70 Ste 2
Brick, NJ 08723-4023
732.279.0200

4, 2026 5:21 PM
ipt #: MJKK00761303

x Express $20.35
x 2Day
71797311

pient Address
iva Biologics Inc.
: Corporate Secretary/Bd of Dir
Medical Center Dr
VILLE, MD 20850, US
000-0000
duled Delivery Date: 06/08/2026
ing Option: One Rate
age Information: FedEx Envelope
ftional Services:
ct Signature Required
K_ONE_RATE
ge Weight: .15 lb (S)
red Value: $100

Express $20.35
2Day
1855082

ient Address
slie Marlow, Esq.
Rome LLP
ve of the Americas
K CITY, NY 10020, US
-0000
ed Delivery Date: 06/08/2026
Option: One Rate
Information: FedEx Envelope
al Services:
Signature Required
E_RATE
Weight: .15 lb (S)
d Value: $100

BLANKROME
1271 Avenue of the Americas | New York, NY 10020
blankrome.com

Phone: (212) 885-5345
Fax: (917) 332-3736
Email: andrew.hambelton@blankrome.com

June 24, 2026

BY E-MAIL AND OVERNIGHT MAIL

Mr. Paul Bernhardt
[redacted]
Toms River, NJ [redacted]
Email: pfbernhardt@yahoo.com

Re: Response to Demand to Certain Corporate Records of Theriva Biologics, Inc. Pursuant to Nevada Revised Statutes §§ 78.105 and 78.257

Dear Mr. Bernhardt:

We represent Theriva Biologics, Inc. ("Theriva" or the "Company"). I write in response to your letters dated June 16, 2026,[1] demanding inspection of certain corporate records of the Company pursuant to Nevada Revised Statutes §§ 78.105 and 78.257 (the "Demands").[2] The Demands are rejected.

The Demands, like your Previous Demand, are improper demands under Nevada Revised Statute § 78.257 because you still lack standing under Section 78.257(1) to make the Demands. As noted in our June 10, 2026 response letter, Section 78.257(1) confers inspection rights only on those stockholders of record who "own [] not less than 15 percent of all of the issued and outstanding shares of the stock of such corporation." Because you do not own 15% or more of the outstanding stock of the Company, you do not have standing under Section 78.257 to demand inspection. You also still fail to include the proper affidavit required by Section 78.257(2). While the Demands include affidavits, the affidavits fail to include that the Demands are "not desired for any purpose not related to [your] interest as a stockholder," as required by Section 78.257(2). Moreover, and again as explained to you in our June 10, 2026 response letter, even if you had standing to issue the Demands, because the Company has filed its required reports with the Securities and Exchange Commission, it is exempted from inspection demands under Section 78.257. Specifically, Section 78.257(7) makes clear the inspection rights in Section 78.257(1) do not apply to publicly traded companies such as Theriva that have "filed during the preceding 12 months all reports required to be filed pursuant to section 13 or section 15(d) of the Securities Exchange Act." Accordingly, to the extent the Demands seek inspection of certain Company records pursuant to Nevada Revised Statute

[1] The letters we received from you dated June 16, 2026 are identical, except for the included affidavits which are notarized by different notaries.
[2] We note that the Demand is substantively identical to the demand you previously made via letter dated June 4, 2026 (the "Previous Demand"), which was rejected by the Company for the reasons stated in the Company's response letter dated June 10, 2026.



BLANKROME

§ 78.257, they are rejected.

The Demands are also rejected to the extent they seek Company records pursuant to Nevada Revised Statute § 78.105. Section 78.105 permits inspection only of very limited categories of records, including the Company's articles of incorporation, bylaws, and stock ledger. While the Demands cite Section 78.105, the substance of the Demands does not seek the limited categories of documents permitted under Section 78.105. Specifically, the Demands seek only records of meeting minutes, voting records, attorney-client communications and proxy solicitation invoices—none of which are proper categories of records for inspection under Section 78.105. Thus, the Demands are rejected. To the extent that you wish to inspect the limited categories of documents under Section 78.105, the Company will consider that upon receipt of a proper demand.

Finally, as noted in our Previous Response, the Company disclosed in its public filings that on each of December 15, 2025, February 11, 2026, April 9, 2026, and June 5, 2026, it called to order its Special Meeting of Stockholders and that at each such time, there were not present or represented by proxy a sufficient number of shares of the Company's common stock to constitute a quorum. As a result, the Company was not able to convene the Special Meeting on any of December 15, 2025, February 11, 2026, April 9, 2026, or June 5, 2026. Because the Special Meeting did not occur, there are no minutes of a meeting that did not take place.

The Company reserves all rights and defenses and waives none.

Very truly yours,

Andrew T. Hambelton

cc: Steven A. Shallcross (via email)
Leslie Marlow, Esq. (via email)

Meeting draft

From: paul bernhardt (pfbernhardt@yahoo.com)
To: pfbernhardt@yahoo.com
Date: Tuesday, December 16, 2025 at 01:13 PM EST

I attended the Theriva Biologics special meeting to approve 16mil new warrants on Monday 12/15. Stephen Shallcross and company attorney Lesley MARK? attended by Zoom and quickly moved tc the meeting for lack of proxy quorum but another attendee Mark Nejmea wouldn't let it happen. He seemed to really know his stuff, engaging the reps with a series of questions which prompted more few silent pauses. Nejmeh asked if Shallcross was continuing a pattern of a stock dilution death spi tovx similar to the fate of prior companies where Shallcross had direct involvement. This guy Nejm was on fire suggesting that Shallcross et al were working in an organized pattern, perhaps criminal, suggestion that the CEO denied. When asked how much new capital the warrant proposal would br Shallcross again declined to comment. In what appears to be a move to send 16 mil warrants to a sp class of investors, ie not you and me, it was clear to the three of us in the room that Shakespear's qu somethings rotten in Denmark' was apropos for this almost non-meeting meeting. A new special m was scheduled for the following Monday 12/22 but I discovered the rescheduled meeting and the w proposal has been scrapped and a new warrant proposal would be filed within 60 days. At the end meeting, I requested a transcript of the proceedings, and Nejmeh also requested that the meeting be broadcast so all shareholders could hear first hand what's being disclosed...or not.